Case Report
Volume: 6 | Issue: 2 | Published: Feb 28, 2022 | Pages: 39 - 42 | DOI: 10.24911/ejmcr/173-1633552787
Mepolizumab-associated acute pancreatitis: a case report
Authors: Fiore Casale , Irum Jan
Article Info
Authors
Fiore Casale
University of New Mexico School of Medicine, Albuquerque, NM, USA
Irum Jan
University of New Mexico, Department of Internal Medicine, Albuquerque, NM, USA.
Publication History
Received: October 11, 2021
Revised: November 30, 2021
Accepted: December 18, 2021
Published: February 28, 2022
Abstract
Background: Drug hypersensitivity reactions commonly generate systemic syndromes but can also affect specific organs. Mepolizumab, a monoclonal antibody targeting interleukin-5, is a safe and effective Food and Drug Administration-approved biologic therapy for severe eosinophilic asthma. Case Presentation: A 49-year-old female developed acute pancreatitis complicated by acute hypoxic respiratory failure secondary to fluid overload. Following 72 hours of intravenous fluids and analgesic administration, an urticarial rash developed on the patient's trunk, raising concern for a drug-related exanthem. After medication reconciliation, it was deemed that she had a hypersensitivity reaction to mepolizumab. Conclusion: In several clinical trials, mepolizumab demonstrated few hypersensitivity reactions. This patient presentation highlights the importance of strong clinical suspicion for drug hypersensitivities, especially in patients failing to respond to the standard of care for common medical conditions.
Keywords: allergy, hypersensitivity, mepolizumab, pancreatitis, DRESS, green
Pubmed Style
Fiore Casale, Irum Jan. Mepolizumab-associated acute pancreatitis: a case report. EJMCR. 2022; 28 (February 2022): 39-42. doi:10.24911/ejmcr/173-1633552787
Web Style
Fiore Casale, Irum Jan. Mepolizumab-associated acute pancreatitis: a case report. https://ejmcr.com/articles/1282 [Access: October 28, 2024]. doi:10.24911/ejmcr/173-1633552787
AMA (American Medical Association) Style
Fiore Casale, Irum Jan. Mepolizumab-associated acute pancreatitis: a case report. EJMCR. 2022; 28 (February 2022): 39-42. doi:10.24911/ejmcr/173-1633552787
Vancouver/ICMJE Style
Fiore Casale, Irum Jan. Mepolizumab-associated acute pancreatitis: a case report. EJMCR. (2022), [cited October 28, 2024]; 28 (February 2022): 39-42. doi:10.24911/ejmcr/173-1633552787
Harvard Style
Fiore Casale, Irum Jan (2022) Mepolizumab-associated acute pancreatitis: a case report. EJMCR, 28 (February 2022): 39-42. doi:10.24911/ejmcr/173-1633552787
Chicago Style
Fiore Casale, Irum Jan. "Mepolizumab-associated acute pancreatitis: a case report." 28 (2022), 39-42. doi:10.24911/ejmcr/173-1633552787
MLA (The Modern Language Association) Style
Fiore Casale, Irum Jan. "Mepolizumab-associated acute pancreatitis: a case report." 28.February 2022 (2022), 39-42. Print. doi:10.24911/ejmcr/173-1633552787
APA (American Psychological Association) Style
Fiore Casale, Irum Jan (2022) Mepolizumab-associated acute pancreatitis: a case report. , 28 (February 2022), 39-42. doi:10.24911/ejmcr/173-1633552787